Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2002
11/07/2002WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002WO2002088090A2 Pyrazole derived kinase inhibitors
11/07/2002WO2002088084A1 Heterocyclic compound derivatives and medicines
11/07/2002WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002WO2002088078A2 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES
11/07/2002WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002WO2002087613A1 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
11/07/2002WO2002087603A1 Immunopotentiators
11/07/2002WO2002087596A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002WO2002087586A1 Sustained release drug delivery system containing codrugs
11/07/2002WO2002087583A2 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002WO2002087569A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002WO2002087511A2 Modulators of elastase inhibitor secretion
11/07/2002WO2002087424A2 Treatment and diagnosis of macrophage mediated disease
11/07/2002WO2002087336A1 Foot and mouth disease virus vaccine
11/07/2002WO2002079137A8 Interleukin-1 and tumor necrosis factor-alpha modulators and their enantiomers, their synthesis and use
11/07/2002WO2002068614A3 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/07/2002WO2002056708A3 Preparation for improved dietary utilisation
11/07/2002WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002WO2002028424A3 Kyberdrug as autovaccines with immune-regulating effects
11/07/2002WO2002009768A3 Therapeutic polyesters and polyamides
11/07/2002WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002WO2001048187A9 A molecular switch for regulating mammalian gene expression
11/07/2002WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002WO2001015745A9 Method and formula for tumor remission and suppression of cancer
11/07/2002US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002US20020165374 Secreted protein HFEAF41
11/07/2002US20020165355 Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
11/07/2002US20020165343 Growth hormone secretagogues
11/07/2002US20020165242 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
11/07/2002US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002US20020165211 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler
11/07/2002US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002US20020165170 Antagonists that bind CD1d and inhibit activation of CD1d-restricted natural killer (NK) T cells, agents that block CD1d-specific receptors and CD1d decoys and a carrier or diluent; contact dermatitis for example
11/07/2002US20020165164 New effectors of dipeptidyl peptidase IV for topical use
11/07/2002US20020165156 Tumor necrosis factor family and its blocking agent
11/07/2002US20020165155 Crystallization of IGF-1
11/07/2002US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002US20020165134 Emulsion preconcentrates; triglyceride mixture
11/07/2002US20020165123 CXCR4 agonist treatment of hemapoietic cells
11/07/2002US20020164773 Generation of extracellular, polysaccharides of basidiomycetes mushrooms; obtain fungi, propagate in nutrient broths, isolating biomass from culture by precipitation
11/07/2002US20020164748 Enzymatic polypeptide for use in the treatment of inflammation, autoimmune and tissue rejection disorders
11/07/2002US20020164738 Cell death inhibitory protein
11/07/2002US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002US20020164704 Novel human monocyte chemotactic proprotein
11/07/2002US20020164697 Nucleotide sequences coding polypeptides for use in treatment of autoimmune disease
11/07/2002US20020164692 Immune system-related polynucleotides, polypeptides, and antibodies
11/07/2002US20020164600 PD-L2 molecules: novel PD-1 ligands and uses therefor
11/07/2002US20020164390 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
11/07/2002US20020164355 Test to detect antibodies; calibration
11/07/2002US20020164353 Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
11/07/2002US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002US20020164347 Neoglycoproteins
11/07/2002US20020164342 Recombinant cat allergen, Fel dI, expressed in baculovirus for diagnosis and treatment of cat allergy
11/07/2002US20020164331 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
11/07/2002US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002US20020164311 Prevention of organ rejection
11/07/2002US20020164308 Embryonic stem cells and neural progenitor cells derived therefrom
11/07/2002CA2594883A1 Pharmaceutically active uridine esters
11/07/2002CA2447748A1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002CA2446408A1 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
11/07/2002CA2446079A1 Modulators of elastase inhibitor secretion
11/07/2002CA2445861A1 Pharmaceutically active uridine esters
11/07/2002CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002CA2445702A1 Control of compactability through crystallization
11/07/2002CA2445593A1 Genetically modified yt cell line and use thereof
11/07/2002CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002CA2445349A1 Anti-cd40 monoclonal antibody
11/07/2002CA2445348A1 Novel benzylpiperidine compound
11/07/2002CA2445338A1 G-protein coupled receptors
11/07/2002CA2445294A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002CA2445266A1 Foot and mouth disease virus vaccine
11/07/2002CA2444911A1 Fusion molecules and methods for treatment of immune diseases
11/07/2002CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002EP1254953A1 Maturation-promoting agent for immature dendritic cells
11/06/2002EP1254944A1 Dry compositions containing hydrophobic amino acid
11/06/2002EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002EP1254897A1 Tricyclic compounds
11/06/2002EP1254659A1 Stable emulsion compositions
11/06/2002EP1254270A1 Methods and materials relating to cub domain polypeptides and polynucleotides
11/06/2002EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002EP1254266A1 Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
1 ... 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 ... 1172